Registration
|
08:15 - 08:50 |
Welcome note from MarketsandMarkets
|
08:50 - 08:55 |
Opening Remarks from the Chairperson
Jim Kean, Chief Executive Officer, Molecular You
|
08:55 - 09:00 |
BIOMARKER DRUG DISCOVERY AND ASSAY VALIDATION |
Keynote Presentation :Enhanced Biomarker Discovery and Validation Using TMT® Proteomics
Ian Pike, Chief Scientific Officer, Proteome Sciences PLC
|
09:00 - 09:30 |
Spatial Analysis in Ulcerative Colitis and Crohn’s Disease
Jiangwei Zhang, Senior Principal Scientist, Bristol Myers Squibb
|
09:30 - 10:00 |
Development of Methylation and Mutation Panel for Colorectal Cancer
Collin Hudzik, Scientist, EpigenDx
|
10:00 - 10:30 |
Morning Refreshments and Poster Presentation | One-to-One Networking Meetings
|
10:30 - 11:15 |
Next Gen Proteomics identified protein signatures for early pan cancer detection and stratification
Kathy Nevola, Data Scientist, Olink
|
11:15 - 11:45 |
Flow cytometry for biomarker development, clinical trial assays, MRD, and CDx
Scott J. Bornheimer, Associate Director, Medical & Scientific Affairs, BD Biosciences
|
11:45 - 12:15 |
AI and Multimoodal Biomarkers for Personalized Pain Medicine
Carl Saab, Professor, Innovation Lead Digital Health, Cleveland Clinic
|
12:15 - 12:45 |
Identification of cancer cell surface target for antibody drug conjugate development.
Ginette Serrero, CEO, Precision Antibody, A&G Pharmaceutical, Inc. | Precision Antibody
|
12:45 - 13:15 |
Lunch and Poster Presentation | One-to-One Networking Meetings
|
13:15 - 14:15 |
Role of biomarkers in personalized medicine Identifying Variants Associated with Creatinine and Cystatin C Serum Levels in the Top 1% of the Population Provides Insight into the Genetic Architecture of Kidney Function and Chronic Kidney Disease.
Matteo D’Antonio, Assistant Professor, University of California, San Diego
|
14:15 - 14:45 |
Innovative oncology liquid biopsy testing in global markets, from lab testing to CDx
Myles A. Walsh, Director of Business Development, Predicine
|
14:45 - 15:15 |
Microbial Marvels: Unleashing Targeted Drug Discovery with Pragma Bios Innovative Approach to Disease-Associated Small Molecules and Novel Biomarkers
Kareem Barghouti, CEO, Pragma Bio
|
15:15 - 15:45 |
Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings
|
15:45 - 16:30 |
AI-powered multi-omic health analytics
Jim Kean, Chief Executive Officer, Molecular You
|
16:30 - 17:00 |
Closing Remarks from the Chairperson
Jim Kean, Chief Executive Officer, Molecular You
|
17:00 - 17:30 |
Drinks Reception & Networking
|
17:30 - 17:30 |
End of Day 1
|
17:30 - 17:30 |